About Antiviral innate immune response effector IFIT1
Antiviral innate immune response effector IFIT1 (IFIT1) is a protein
from Homo sapiens identified by UniProt accession
P09914, 478 residues long.
MolForge cross-references it against 0 known binders and
251 disease associations.
Target properties
| Protein name | Antiviral innate immune response effector IFIT1 |
| UniProt accession | P09914 |
| Gene | IFIT1 |
| Organism | Homo sapiens |
| Length | 478 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (251)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.28
- genetic disorder · score 0.12
- infection · score 0.10
- infect · score 0.10
- Systemic lupus erythematosus · score 0.09
- cancer · score 0.08
- pancreatic neoplasm · score 0.07
- neoplasm · score 0.07
- non-small cell lung carcinoma · score 0.07
- hepatocellular carcinoma · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P09914-F1 | alphafold | PREDICTED | 94.15 | — |
Amino-acid sequence (478 residues)
MSTNGDDHQV KDSLEQLRCH FTWELSIDDD EMPDLENRVL DQIEFLDTKY SVGIHNLLAY VKHLKGQNEE ALKSLKEAEN LMQEEHDNQA NVRSLVTWGN FAWMYYHMGR LAEAQTYLDK VENICKKLSN PFRYRMECPE IDCEEGWALL KCGGKNYERA KACFEKVLEV DPENPESSAG YAISAYRLDG FKLATKNHKP FSLLPLRQAV RLNPDNGYIK VLLALKLQDE GQEAEGEKYI EEALANMSSQ TYVFRYAAKF YRRKGSVDKA LELLKKALQE TPTSVLLHHQ IGLCYKAQMI QIKEATKGQP RGQNREKLDK MIRSAIFHFE SAVEKKPTFE VAHLDLARMY IEAGNHRKAE ENFQKLLCMK PVVEETMQDI HFHYGRFQEF QKKSDVNAII HYLKAIKIEQ ASLTRDKSIN SLKKLVLRKL RRKALDLESL SLLGFVYKLE GNMNEALEYY ERALRLAADF ENSVRQGP
Explore Antiviral innate immune response effector IFIT1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets